Inogen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INGN research report →
Range $26 – $26
Price Chart
About the company
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions.
- CEO
- Andrew Reding
- IPO
- 2014
- Employees
- 753
- HQ
- Beverly, MA, US
Get TickerSpark's AI analysis on INGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $137.81M
- P/E
- -4.05
- Fwd P/E
- 106.00
- PEG
- 0.10
- P/S
- 0.41
- P/B
- 0.89
- EV/EBITDA
- -3.57
- Div Yield
- 0.00%
- Gross Margin
- 47.26%
- Op Margin
- -11.33%
- Net Margin
- -10.46%
- ROE
- -20.06%
- ROIC
- -19.17%
Latest fiscal year · YoY change
- Revenue
- $348.67M+3.9%
- Gross Profit
- $165.89M+7.2%
- Op Income
- $-30,207,000
- Net Income
- $-22,747,000+36.6%
- EPS
- $-0.85+44.1%
- OCF Growth
- -289.7%
- FCF Growth
- -93.2%
- 52W High
- $7.67
- 52W Low
- $5.04
- 50D MA
- $6.03
- 200D MA
- $6.23
- Beta
- 1.49
- RSI (14)
- 31
- Avg Volume
- 315.66K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Inogen reported a mixed third quarter with U.S. sales returning to growth, but international weakness and restructuring charges kept profitability under pressure.· November 5, 2026
- Total revenue from continuing operations was $77.2 million, down 2.4% year over year, as U.S. growth was offset by softer international spending.
- U.S. sales were $42.2 million, up 3.8%, and POC unit volume rose nearly 6% to 51.9 thousand units.
- International sales fell 9% to $34.9 million, mainly due to weaker capital spending and inventory management at large European customers.
- Adjusted gross margin was 44.2% versus 45.9% last year; adjusted operating expenses declined 4.4% to $35.3 million.
- Management announced an additional $20 million annualized cost savings program and raised full-year revenue guidance while shifting profitability reporting to adjusted net loss.
In the third quarter, total revenue from continuing operations was $77.2 million, down 2.4% from $79.1 million a year ago, or down 3.2% on a constant-currency basis. U.S. sales rose 3.8% to $42.2 million, while international sales declined 9% to $34.9 million. POC unit volume increased nearly 6% year over year to 51.9 thousand units. Adjusted gross margin was 44.2% versus 45.9% in the prior-year period. GAAP loss from continuing operations was $14.8 million, including a $10.6 million non-cash goodwill impairment, and adjusted net loss from continuing operations was $400 thousand, or $0.02 per diluted share, versus adjusted net earnings of $1.2 million, or $0.04 per share, last year. For the fourth quarter, management expects revenue of $65 million to $68 million. Full-year 2026 revenue from continuing operations is guided to $298 million to $301 million, and full-year adjusted net loss from continuing operations is expected to be $7 million to $8 million.
Andrew Reding said he joined Inogen because of its market-leading core business, differentiated portfolio, and untapped potential, and framed his early focus as simplifying the company, improving commercial execution, and restoring profitable growth. He emphasized that the U.S. oxygen rental divestiture makes Inogen a more focused company and that U.S. sales have returned to year-over-year growth for the first time since the fourth quarter of 2024. His tone was confident but candid, repeatedly noting that results are not where they need to be and that the company must execute with urgency and discipline.
Jason Richardson focused on the divestiture, saying the rental business closed on November 2 for estimated cash consideration of up to $24.8 million, expected in the first half of 2027. He highlighted adjusted gross margin of 44.2%, adjusted operating expenses of $35.3 million, and negative operating cash flow of $4.5 million due to working capital. He also noted $97.7 million of cash, cash equivalents, marketable securities, and restricted cash, no debt outstanding, $11.2 million of share repurchases year to date, and an expanded authorization of $45 million. He said the new cost program should generate about $20 million in annualized savings by the end of 2027, with the first $10 million completed before the end of 2026.
There was no live Q&A session; management said this was Andrew Reding’s first earnings call and that they would not take live questions. Instead, Reding reiterated the main messages: the company is becoming more focused, strengthening execution, returning the business to profitable growth, and expanding beyond portable oxygen into adjacent respiratory areas such as sleep and airway clearance. The only notable issue addressed was the expected continued softness in international markets, which management said should persist into the fourth quarter after stronger demand earlier in the year.
The bull case from the call is that Inogen is showing signs of stabilization in the U.S., with sales growth, nearly 6% unit growth, and new products contributing about 250 basis points. Management also pointed to the divestiture, a stronger focus on core portable oxygen, and a new $20 million cost savings program as steps toward improved profitability.
The bear case is that overall revenue still declined, international sales were weak, and management expects that softness to continue into the fourth quarter. Profitability remains thin, GAAP results included a $10.6 million goodwill impairment, and cash from operations was negative in the quarter due to working capital needs. The company is also still in the process of proving that new products and restructuring can translate into sustained profitable growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.9%
- Shares Outstanding
- 26.00M
- Float Shares
- 22.59M
of shares held by institutions
128 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for INGN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lamar Seeligson SmithHouse · TX21 | Buy | Nov 20, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.74M | ▼ 4.20K |
| Vanguard Group Inc | 1.42M | ▼ 8.99K |
| Armistice Capital, LLC | 1.24M | ▲ 140.00K |
| Acadian Asset Management LLC | 1.10M | 0 |
| Vanguard Capital Management LLC | 1.04M | 0 |
| Dafna Capital Management LLC | 845.18K | 0 |
| Arrowstreet Capital, Limited Partnership | 778.08K | ▲ 34.83K |
| Morgan Stanley | 691.59K | ▲ 45.31K |
| Jpmorgan Chase & Co | 679.87K | ▲ 199.56K |
| Aqr Capital Management LLC | 654.63K | ▼ 282.70K |
| State Street Corp | 591.58K | ▼ 359 |
| Federated Hermes, Inc. | 566.03K | ▲ 31.10K |
Held by 128 ETFs
Biggest fund positions in INGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Wright Mary E | other | 1,500 |
| Sep 1, 26 | Smith Kevin P. | other | 18,136 |
| Sep 1, 26 | Smith Kevin P. | other | 8,671 |
| Sep 1, 26 | Smith Kevin P. | other | 1,500 |
| Sep 1, 26 | Smith Kevin P. | other | 18,136 |
| Sep 1, 26 | Smith Kevin Raymond Merrill | other | 1,500 |
| Jul 6, 26 | Reding Andrew P. | other | 130,000 |
| Jul 6, 26 | Reding Andrew P. | other | 0 |
| Jul 1, 26 | Yi Boyer Jennifer M | sell | 10,938 |
| Jun 5, 26 | Sahney Mira Kirti | other | 28,081 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INGN coverage
Recent articles, reports, and earnings notes.
No research on INGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INGN report →Inogen, Inc. (INGN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Inogen (INGN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Inogen Announces Third Quarter 2026 Financial Results
businesswire.com · Nov 5
Inogen Announces Leadership Transition
businesswire.com · Nov 5
Inogen: Cheap Enough To Take A Chance On
seekingalpha.com · Oct 20
Inogen (NASDAQ:INGN) Share Price Breaks Above Fifty Day Moving Average – Should You Sell?
defenseworld.net · Oct 20
Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
businesswire.com · Oct 15
Inogen (NASDAQ:INGN) Stock Price Breaks Above Fifty Day Moving Average – What’s Next?
defenseworld.net · Oct 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.